Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry

Table 1 Identified LAMP2 peptides by employing hybrid immunoprecipitation nano-LC–MS/MS

Sequence^a	Peptide^b	Mascot ion score	Mascot expect	Fragment ions^c
WQMNFTVR	LAMP2 aa 46–53	36	4.8 × 10⁻³	–
GILTVDELLAIR	LAMP2 aa 133–144	81	6.9 × 10⁻⁸	y5, y6, y7, y8, y9
IPLNDLFR	LAMP2 aa 145–152	50	2.2 × 10⁻⁴	y4, y5, y6, y7
CNSLSTLEK	LAMP2 aa 153–161	59	2.7 × 10⁻⁵	y4, y5, y6, y7
YLDFVFAVK	LAMP2 aa 281–289	33	1.5 × 10⁻²	–
EQTVSVSGAFQINTFDLR	LAMP2 aa 334–351	101	1.7 × 10⁻⁹	y6, y7, y8, y9, y10, y11, y12, y13, y14
LGEYGFQNALIVR	BSA aa 421–433	–	–	y4, y6, y7, y8, y9, y10

The table shows the LAMP2 peptides identified in human CSF by nano-LC–MS/MS. The identification statistics values are shown for the peptides identified with highest confidence
^aCysteine’s were subjected to carbamidomethylation through alkylation
^bThe name of the peptides are given according to their amino acid (aa) sequence position
^cFragment ions used for quantitation and evaluating the HR-PRM-MS method as well as the fragment ions of the added BSA peptide

ISSN: 1559-0275